The late effects of cranial irradiation in childhood on the hypothalamic–pituitary axis: a radiotherapist's perspective. Issue 12 (17th November 2022)

• Record Type: Journal Article
• Authors: Lövgren, Izabelle; Abravan, Azadeh; Bryce-Atkinson, Abigail; van Herk, Marcel
• Is Part Of: Endocrine connections. Volume 11:Issue 12(2023)
• Publication Date: 2022-11-17
• Subjects: neuroendocrine disruption -- hypothalamic–pituitary axis -- radiotherapy -- hormone deficiency; Endocrinology -- Periodicals; 616.4005
• DOI: 10.1530/EC-22-0298
• Languages: English
• ISSNs: 2049-3614

Abstract

Abstract : Brain tumours make up nearly one-third of paediatric malignancies. Over time, advancements in oncological treatments like radiotherapy have helped reduce normal-tissue toxicity when treating cancers in the brain. However, clinicians are still facing a trade-off between treatment efficacy and potential side effects. The aim of this review is to address the late effects of cranial irradiation on the neuroendocrine system and to identify factors that make patients more vulnerable to radiation-induced endocrine sequelae. Radiation damage to the hypothalamic–pituitary axis, which orchestrates hormone release, can lead to endocrinopathy; up to 48.8% of children who have undergone cranial irradiation develop a hormone deficiency. This may lead to further health complications that can appear up to decades after the last treatment, lowering the patients' quality of life and increasing long-term costs as lifelong hormone replacement therapy may be required. Growth hormone deficiency is the most common sequelae, followed by either thyroid or gonadotropic hormone deficiency. Adrenocorticotropic hormone deficiency tends to be the least common. Identified factors that increase the risk of late endocrine deficiency include total radiation dose, age at treatment, and time since last treatment. However, as there are various other factors that may potentiate the damage, a universal solution proven to be most effective in sparing the endocrine tissues is yet to be identified. Until then, accounting for the identified risk factors during treatment planning may in some cases help reduce the development of endocrine sequelae in childhood cancer survivors.